# Adial Pharmaceuticals, Inc. (ADIL)

> Source: Nexqual · https://nexqual.com/ADIL · data as of 2026-10-23 20:00 UTC · cite as "Nexqual, Adial Pharmaceuticals, Inc. (ADIL), nexqual.com/ADIL" · informational, not investment advice.

**Price:** USD 3.92 (-7.11% on the day) · last close of Oct 23, 2026; US market closed, not a live price. Prev close 4.22 · day 3.92–4.28 · 52w 1.31–9.5 · market cap $10.3M · NCM

## Key facts
- Insider open-market purchases, last ~7 months: 3 Form 4 filings, $106K; 0 by opportunistic insiders, 0 by routine insiders.
- Total return with dividends: 1Y -56.4% vs S&P 500 +13.4%; 5Y -99.8% vs S&P 500 +76.9%.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Operating income | -$19.3M | -$10.9M | -$6.9M | -$8.3M | -$7.8M | -$57.7M |
| Net income | -$19.4M | -$12.7M | -$5.1M | -$13.2M | -$8.0M | -$57.8M |
| EPS (diluted) | -$650.00 | -$317.75 | -$90.00 | -$68.01 | -$11.93 | — |
| Free cash flow | -$12.0M | — | — | — | — | — |
| Cash + short-term investments | $6.1M | $4.0M | $2.8M | $3.8M | $5.9M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
Earnings yield -561.54%

## Insider purchases (SEC Form 4, open-market, last ~7 months)
3 purchases, $106K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-07-14…2026-07-16 | Coastlands Capital Lp |  | 3,233 | $9K | 2.69 | Too little history (no open-market trades in 2023–2025) |
| 2026-07-09…2026-07-10 | Coastlands Capital Lp |  | 11,753 | $33K | 2.78 | Too little history (no open-market trades in 2023–2025) |
| 2026-06-29 | Coastlands Capital Lp |  | 25,000 | $65K | 2.6 | Too little history (no open-market trades in 2023–2025) |
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Analysts
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-03 | Alliance Global Partners | Initiated | Buy | $11 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-24) | 5Y (from 2021-10-25) |
|---|---|---|
| Total return | -56.4% | -99.8% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | -56.6% | -71.3% |
| Volatility (annualized) | 101.2% | 122.1% |
| Max drawdown | -85.7% (Oct 2025→May 2026) | -99.9% (Nov 2021→May 2026) |

## Peers (Biotechnology)
LGND (Ligand Pharmaceuticals Incorpor) USD 303.53 -1.39% · RYTM (Rhythm Pharmaceuticals, Inc.) USD 89.27 -1.79% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.09 -0.35% · PRAX (Praxis Precision Medicines, Inc) USD 252.96 -2.30% · IONS (Ionis Pharmaceuticals, Inc.) USD 42.93 -2.23% · AXSM (Axsome Therapeutics, Inc.) USD 145.04 -7.07%

## More
Full page: https://nexqual.com/ADIL · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Company outlook (8-K filed 2026-08-17)

- "The $38.5 million attributable to the Series A convertible preferred stock is expected to be reclassified as equity upon obtaining stockholder approval of its conversion to common stock."

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-2.58 | $-1.31 | +96.6% | $0 | 2 |
| Next quarter (ends 2026-12-31) | $-2.59 | $-0.80 | +223.7% | $0 | 2 |
| Current fiscal year (ends 2026-12-31) | $-1.05 | $-6.12 | -82.8% | $0 | 1 |
| Next fiscal year (ends 2027-12-31) | $-7.45 | $-2.59 | +187.6% | $0 | 2 |